BioSpectrum, 24th anniversary: the business of Bio and Health Sciences
World AMR Awareness Week | 18 to 24 November 2026One Health, one action: Prevent AMR now
BioSpectrum India Podcast | AMR Week Special

Fighting the silent pandemic

Thirty years ago, as big pharma walked away from antibiotics, one Indian company kept going. Wockhardt's Founder Chairman talks about building new antibiotics in India, saving patients nothing else could help, and the reforms India needs next.

Dr. Habil KhorakiwalaFounder Chairman, Wockhardt Group
Video podcast23 minEnglish9 AMR explainers
See resistance happen
NOWPress play to watch the full conversation.
Dr. Habil Khorakiwala, Founder Chairman, Wockhardt Group
Dr. Habil KhorakiwalaFounder Chairman, Wockhardt Group
From the conversation
Can we make our antibiotic accessible equally, irrespective of your buying power? You have a drug, you make it available to as many people as possible.
Dr. Habil KhorakiwalaOn taking new antibiotics to the world. Lightly edited for readability.
See resistance happen

What happens when a course is cut short

A live model of an infection. Grey bacteria die quickly on the antibiotic, amber ones are tougher, and red ones are fully resistant. Bacteria double about every six hours. Try a full course, then try stopping early a few times, and watch the mix change.

Time0 h
Bacteria0
Tough or resistant0%
AntibioticOff
Every hour counts

How fast does an untreated infection grow?

Dr. Khorakiwala's point: bacteria can double every six hours, so a delay in the right treatment multiplies the infection. Drag to see.

16×
more bacteria after 1 day: 1 million becomes 16 million
AMR in numbers

Why this conversation can't wait

Drug-resistant infections already kill more than a million people a year. These are the figures behind the episode.

0

people have died as a direct result of drug-resistant infections worldwide since you opened this page.

Estimate based on 1.14 million deaths a year directly caused by AMR, about 2 every minute. Source: GRAM Project, The Lancet (2024), data for 2021.
39M+
deaths from AMR forecast between 2025 and 2050
GRAM Project, The Lancet (2024)
267K
deaths in India caused directly by drug-resistant infections in 2021
IHME / GRAM estimates for India
15 of 90
antibacterials in clinical development qualify as innovative
WHO pipeline analysis, 2025
92M
lives that better infection care and access to antibiotics could save by 2050
GRAM Project, The Lancet (2024)

1 in 6 lab-confirmed bacterial infections worldwide now resist antibiotics. In South-East Asia, it is 1 in 3.

Source: WHO Global Antibiotic Resistance Surveillance Report (GLASS), 2025
In his words

Five lines from the conversation

Quotes are lightly edited for readability. Tap a quote's timestamp to hear it in context.

"You have to get the right antibiotic, at the right time, to the right kind of patients."
On stewardship
"Ordinary people should never use antibiotics on their own."
On public awareness
"For every six hours, the population of bacteria doubles. Every day is very precious for life."
On precision stewardship
"We intend to invest in antibiotic research over the next 20 to 30 years."
On Wockhardt's commitment
"India can definitely become an innovative hub in the world."
On India's future
The takeaway

Three things India must do now

Asked to sum up, Dr. Khorakiwala named three priorities for the country's fight against AMR.

01

Regulatory reform

India's system is built to approve generics and biosimilars. It needs the capacity to evaluate truly new drugs, so innovators don't lose three to four years.

02

Patent alignment

Bring the patent framework in line with Western markets so global companies invest and run research in India.

03

Precision stewardship

Don't simply hold new antibiotics back. Give the right drug at the right time, because every day of delay lets infection grow.

Test yourself

How well do you know AMR?

Three quick questions drawn from the episode and its explainers.

Dr. Habil Khorakiwala

Dr. Habil Khorakiwala

Founder Chairman, Wockhardt Group

Led Wockhardt into antibiotic research some 30 years ago, when most large companies were leaving the field.

  • Research baseWockhardt's research centre in Aurangabad, with a team of Indian scientists and 30 to 35 academic and surveillance partners
  • Published workAbout 200 scientific papers in global journals over the programme's life
  • MilestoneZaynich (cefepime + zidebactam) won US FDA approval in May 2026, the first new chemical entity fully developed by an Indian company to do so
  • Patients helped85 lives saved through compassionate use before approval, in patients where nothing else was working
  • MissionEqual access to new antibiotics in developed and emerging markets, irrespective of buying power
Spread the word

Share this episode during AMR Week